Recently, Sanofi alongside Regeneron obtained FDA approval for Dupixent to treat a rare skin disease. The drug company is expediting vaccine development in an alliance with Abu Dhabi. Sanofi has been actively incorporating the M&A strategy to expand its business, evident from its decisions to acquire Blueprint Medicines and Vigil Neuroscience for $9.5 billion and $470 million respectively. Other newsworthy features include their revolutionary Sarclisa SC, and the race with Merck and AstraZeneca to provide an RSV shot for infants. The massive $130M flagship office facility in New Jersey also marks their increasing presence in the US. However, the firm experienced a setback with their drug used to treat COPD, jointly developed with Regeneron, failing the key test. In the meantime, Sanofi is in collaboration talks with Vietnamese partners regarding vaccine production, and is slated to invest at least $20 billion in the US through 2030.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sat, 21 Jun 2025 17:29:37 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor -2
